Enrollment progressing in Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Top-line data in the first cohort of RGLS8429-treated ADPKD patients anticipated in second half of .
SAN DIEGO, Jan. 13, 2023 /PRNewswire/ Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today. | January 13, 2023